MedicalResearch.com Interview with:
Anton Wellstein, MD PhD
Professor Oncology & Pharmacology
Georgetown University Medical School
Associate Director for Basic and Translational Science
Lombardi Comprehensive Cancer Center
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Tumor angiogenesis and signaling by growth factors such as Fibroblast growth factors (FGFs) are targets for the treatment of cancer. Targeting some of these factors will alter blood pressure. We show that FGF activation in an animal model can cause hypertension. We show that the hypertension is driven by sensitization of resistance vessels to the vasoconstrictor angiotensin II. We propose that drugs used to target FGF pathway signaling in cancer could be useful to treat hypertension.
MedicalResearch.com: What should readers take away from your report?
Response: Drugs that target FGF pathway activation in cancer may be useful in treating hypertension.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Extend the preclinical studies in hypertension models to test the hypothesis; evaluate if FGF targeted drugs when used in hypertensive patients impact their hypertension.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Blood Pressure Control by a Secreted FGFBP1 (Fibroblast Growth Factor–Binding Protein)
Elena Tassi, En Yin Lai, Lingli Li, Glenn Solis, Yifan Chen, William E. Kietzman, Patricio E. Ray, Anna T. Riegel, William J. Welch, Christopher S. Wilcox, Anton Wellstein
Originally published November 20, 2017
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.